Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 4, 2001

View Archived Issues

Phase II trial to compare two ciprofloxacin formulations for urinary tract infections

FDA accepts for review Picovir NDA for use in the common cold

AtheroGenics begins phase I trial of AGIX-4207 for rheumatoid arthritis

ICN acquires promising liver-targeting hepatitis B compound

FDA approves Dermagraft living human dermal substitute

Chromax dietary supplement undergoes clinical testing for treatment of depression

Marine sponge-derived compound with antiinflammatory properties

Sch-351125: an orally bioavailable anti-HIV CCR5 antagonist

Human monoclonal antibody targeting IL-15 advances to clinical trials in RA patients

Molsidomine reduces upregulated prostacyclin synthase mRNA in hypoxic pulmonary hypertension

Antinociceptive effects demonstrated for the synthetic cannabinoid HU-210

Pharmacological profile of PTK-787/ZK-222584, a new, orally active angiogenesis inhibitor

Divalproex as a treatment strategy for alcohol withdrawal syndrome

Progenics licenses drug in clinical development for reducing peripheral opioid side effects

NIH supports development of inhaled gene therapy for hemophilia B

Topiglan well tolerated by both males and their female partners during intercourse

GSK develops highly potent and selective COX-2 inhibitors

VEGF receptor tyrosine kinase inhibitors and their use in cancer

New oxazolidinone antibacterial agents with broad-spectrum activity

Aventis patents new series of bone resorption inhibitors

P&G compounds reportedly useful for treating and preventing ischemia-reperfusion injury

AstraZeneca team discovers inhibitors of iNOS useful for inflammation and pain

Inhibitors of beta-amyloid aggregation claimed by JT for use in dementia

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 16, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...